CN Blog Bios

April 13, 2010

Derek Raghavan, MD, PhD, FACP, is Chairman and Director of the Cleveland Clinic Taussig Cancer Center. Dr. Raghavan was trained in Medicine and Oncology at the University of Sydney, Australia. He obtained a PhD in experimental pathology from the University of London/Ludwig Institute for Cancer Research, and then completed post-doctoral studies at the University of Minnesota.  Dr. Raghavan has produced about 300 scientific papers, and has edited 9 books. His clinical and research interests are focused on genitourinary cancer, cancer in the elderly, disparities of cancer care, anticancer drug discovery and development and comparative human oncology.

Derek Raghavan, MD, PhD, FRACP raghavd@ccf.org

Derek Raghavan, MD, PhD, FACP, is Chairman and Director of the Cleveland Clinic Taussig Cancer Center. Dr. Raghavan was trained in Medicine and Oncology at the University of Sydney, Australia. He obtained a PhD in experimental pathology from the University of London/Ludwig Institute for Cancer Research, and then completed post-doctoral studies at the University of Minnesota.  Dr. Raghavan has produced about 300 scientific papers, and has edited 9 books. His clinical and research interests are focused on genitourinary cancer, cancer in the elderly, disparities of cancer care, anticancer drug discovery and development and comparative human oncology.

Andrew D. Seidman, MDseidmana@MSKCC.ORG

Dr. Andrew D. Seidman is an Attending Physician for the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Joan and Sanford I. Weill Medical College of Cornell University.  He received his medical school training at the Hahnemann University School of Medicine and a residency in Internal Medicine at The Pennsylvania Hospital. He then completed a fellowship in Medical Oncology and Hematology at MSKCC.  Dr. Seidman is the recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO) for his clinical research evaluating the role of the taxanes in breast cancer treatment.